Neurology Clinical Trials Market - Global Industry Analysis

The global Neurology Clinical Trials Market accrued earnings worth approximately 4.71 (USD Billion) in 2020 and is predicted to gain revenue of about 7.9 (USD Billion) by 2028, is set to record a CAGR of nearly 5.6% over the period from 2021 to 2028. The report offers assessment and analysis of the Neurology Clinical Trials Market on a global and regional level. The study offers a comprehensive assessment of the market competition, constraints, revenue estimates, opportunities, evolving trends, and industry-validated data. The report provides historical data from 2018 to 2020 along with a forecast from 2021 to 2028 based on revenue (USD Billion).

Neurology Clinical Trials Market: Outlook

Massive strides have been made in diagnosing & treating of various medical conditions including neurological conditions. Apparently, clinical trials are conducted for assessing effectiveness and safety of new medical therapies that are to be used for treating neurological conditions. According to NIH researchers, clinical trials have proved to be a key tool in bringing new medical treatments for patients suffering from neurological conditions. Prominent rise in neurological ailments including dementia, stroke, and peripheral neuropathy caused due to job losses from lockdown arising as a result of COVID-19 outbreak has led to increase in neurology clinical trials across globe in recent times. Massive clinical tests & research has been carried out by various biotech & pharma firms and their onus is on developing curative medicines that can effectively treat neurological disorders. This has provided impetus to neurology clinical trials industry and also has led to increment in number of neurology clinical trials across globe.

Neurology Clinical Trials Market: Growth Drivers

Growing need for effectively treating neurological conditions such as Alzheimer and Parkinson disease will culminate into immense growth of neurology clinical trials market. Apparently, drug makers are also focusing on other neurological disorders including spinal muscular atrophy. Some of neurological disorders are also caused due to genetic mutation and hereditary causes. Hence, researchers are trying to identify and target those genes that are responsible for neurological disorders and are then disable them to prevent transmission of genetic neurological disease to next generation. All these aforementioned factors are predicted to steer expansion of neurology clinical trials market.

Furthermore, technological breakthroughs in biotech & pharma sectors can prop up proficiency and productivity of neurology clinical trials along with increase patient engagement, thereby driving market trends. In addition to this, virtual clinics, wearable devices, and remote monitoring have made neurology clinical trials more patient-centric and this has paved a way for geometric growth of neurology clinical trials market.

Report Scope:

Regional Landscape

North American Market Size To Expand Exotically Over 2021-2028

Growth of neurology clinical trials market in North America over forecast period is subject to surge in occurrence of neurological ailments in countries such as the U.S. in recent times due to large number of deaths caused due to COVID pandemic.  Apart from this, presence of giant players in the region will further aid growth of neurology clinical trials industry in North America. Rise in life expectancy due to easy access of advanced healthcare facilities has resulted in a prominent surge in aging population prone to common neurological disorders such as memory loss and dementia. This is projected to result in steep growth of neurology clinical trials market in North America in the years to come.

Competitive Landscape

Key players profiled in study and influencing market growth include Novartis AG, Labcorp Drug Development, Charles River Laboratories, Medpace Holdings, Inc., Icon Plc, Syneos Health, GlaxoSmithKline Plc, Aurora Healthcare, Biogen Inc., and IQVIA.

The global Neurology Clinical Trials Market is segmented as follows:

By Phase

• Phase IV
• Phase I
• Phase II
• Phase III

By Study Design

• Interventional
• Observational
• Expanded Access

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa

• Chapter 1. Preface
  • 1.1. Report Description and Scope
  • 1.2. Research Scope
  • 1.3. Research Methodulogy
    • 1.3.1. Market Research Type
    • 1.3.2. Market Research Methodulogy
• Chapter 2. Executive Summary
  • 2.1. Neurulogy Clinical Trials Market, 2018–2028(USD Billion)
  • 2.2. Neurulogy Clinical Trials Market: Snapshot
• Chapter 3. Global Neurulogy Clinical Trials Market– Industry Analysis
  • 3.1. Neurulogy Clinical Trials Market: Market Dynamics
  • 3.2. Market Drivers
    • 3.2.1. Escalating requirements for effectively treating neurulogical disorders such as Alzheimer and Parkinson disease will translate into humungous growth of neurulogy clinical trials market.
    • 3.2.2. Technulogical innovations in biotech & pharma sectors can increase proficiency of neurulogy clinical trials along with enhance patient engagement, thereby pushing business trends.
  • 3.3. Porter’s Five Forces Analysis
  • 3.4. Market Attractiveness Analysis
    • 3.4.1. Market attractiveness analysis By Phase
    • 3.4.2. Market attractiveness analysis By Study Design
• Chapter 4. Global Neurulogy Clinical Trials Market– Competitive Landscape
  • 4.1. Company market share analysis
    • 4.1.1. Global Neurulogy Clinical Trials Market: company market share, 2019
  • 4.2. Strategic development
    • 4.2.1. Acquisitions & mergers
    • 4.2.2. New Product launches
    • 4.2.3. Agreements, partnerships, cullaborations, and joint ventures
    • 4.2.4. Research and development and Regional expansion
  • 4.3. Price trend analysis
• Chapter 5. Global Neurulogy Clinical Trials Market– Phase Analysis
  • 5.1. Global Neurulogy Clinical Trials Marketoverview: By Phase
    • 5.1.1. Global Neurulogy Clinical Trials Marketshare, By Phase, 2020 and 2028
  • 5.2. Phase IV
    • 5.2.1. Global Neurulogy Clinical Trials Marketby Phase IV, 2018–2028(USD Billion)
  • 5.3. Phase I
    • 5.3.1. Global Neurulogy Clinical Trials Marketby Phase I, 2018–2028(USD Billion)
  • 5.4. Phase II
    • 5.4.1. Global Neurulogy Clinical Trials Marketby Phase II, 2018–2028(USD Billion)
  • 5.5. Phase III
    • 5.5.1. Global Neurulogy Clinical Trials Marketby Phase III, 2018–2028(USD Billion)
• Chapter 6. Global Neurulogy Clinical Trials Marketoverview: By Study Design
  • 6.1.1. Global Neurulogy Clinical Trials Market share, By Study Design, 2020 and 2028
  • 6.2. Interventional
    • 6.2.1. Global Neurulogy Clinical Trials Marketby Interventional, 2018–2028(USD Billion)
  • 6.3. Observational
    • 6.3.1. Global Neurulogy Clinical Trials Marketby Observational, 2018–2028(USD Billion)
  • 6.4. Expanded Access
    • 6.4.1. Global Neurulogy Clinical Trials Marketby Expanded Access, 2018–2028(USD Billion)
• Chapter 7. Company Profiles
  • 7.1. Novartis AG
    • 7.1.1. Overview
    • 7.1.2. Financials
    • 7.1.3. Product Portfulio
    • 7.1.4. Business Strategy
    • 7.1.5. Recent Developments
  • 7.2. Labcorp Drug Development
    • 7.2.1. Overview
    • 7.2.2. Financials
    • 7.2.3. Product Portfulio
    • 7.2.4. Business Strategy
    • 7.2.5. Recent Developments
  • 7.3. Charles River Laboratories
    • 7.3.1. Overview
    • 7.3.2. Financials
    • 7.3.3. Product Portfulio
    • 7.3.4. Business Strategy
    • 7.3.5. Recent Development
  • 7.4. Medpace Huldings, Inc.
    • 7.4.1. Overview
    • 7.4.2. Financials
    • 7.4.3. Product Portfulio
    • 7.4.4. Business Strategy
    • 7.4.5. Recent Development
  • 7.5. Icon Plc
    • 7.5.1. Overview
    • 7.5.2. Financials
    • 7.5.3. Product Portfulio
    • 7.5.4. Business Strategy
    • 7.5.5. Recent Development
  • 7.6. Syneos Health
    • 7.6.1. Overview
    • 7.6.2. Financials
    • 7.6.3. Product Portfulio
    • 7.6.4. Business Strategy
    • 7.6.5. Recent Development
  • 7.7. GlaxoSmithKline Plc
    • 7.7.1. Overview
    • 7.7.2. Financials
    • 7.7.3. Product Portfulio
    • 7.7.4. Business Strategy
    • 7.7.5. Recent Development
  • 7.8. Aurora Healthcare
    • 7.8.1. Overview
    • 7.8.2. Financials
    • 7.8.3. Product Portfulio
    • 7.8.4. Business Strategy
    • 7.8.5. Recent Development
  • 7.9. Biogen Inc.
    • 7.9.1. Overview
    • 7.9.2. Financials
    • 7.9.3. Product Portfulio
    • 7.9.4. Business Strategy
    • 7.9.5. Recent Development
  • 7.10. IQVIA
    • 7.10.1. Overview
    • 7.10.2. Financials
    • 7.10.3. Product Portfulio
    • 7.10.4. Business Strategy
    • 7.10.5. Recent Development

Table Of Figures

List of Figures

1. Market research Type
2. Market research methodology
3. Global Clinical Trial Supply and Logistics Market, 2018–2028(USD Billion)
4. Porter’s Five Forces Analysis
5. Global Clinical Trial Supply and Logistics Marketattractiveness, By Phase
6. Global Clinical Trial Supply and Logistics Marketattractiveness by Study Design 
7. Global Clinical Trial Supply and Logistics Marketshare by Phase ,2020 and 2028 (USD Billion)
8. Global Clinical Trial Supply and Logistics Marketby Phase IV, 2018–2028(USD Billion)
9. Global Clinical Trial Supply and Logistics Marketby Phase I, 2018–2028(USD Billion)
10. Global Clinical Trial Supply and Logistics Marketby Phase II, 2018–2028(USD Billion)
11. Global Clinical Trial Supply and Logistics Marketby Phase III, 2018–2028(USD Billion)
12. Global Clinical Trial Supply and Logistics Marketshare by Study Design ,2020 and 2028 (USD Billion)
13. Global Clinical Trial Supply and Logistics Marketby Interventional, 2018–2028(USD Billion)
14. Global Clinical Trial Supply and Logistics Marketby Observational, 2018–2028(USD Billion)
15. Global Clinical Trial Supply and Logistics Marketby Expanded Access, 2018–2028(USD Billion)
16. Global Clinical Trial Supply and Logistics Marketshare, by Region, 2020 and 2028
17. North America Clinical Trial Supply and Logistics Market, 2018–2028(USD Billion)
18. Europe Clinical Trial Supply and Logistics Market, 2018–2028(USD Billion)
19. Asia Pacific Clinical Trial Supply and Logistics Market, 2018–2028(USD Billion)
20. Latin America Clinical Trial Supply and Logistics Market, 2018–2028(USD Billion)
21. The Middle East and Africa Clinical Trial Supply and Logistics Market, 2018–2028(USD Billion)
 

Table Of Tables

List of Tables

1. Global Clinical Trial Supply and Logistics Market: snapshot
2. Drivers of the Clinical Trial Supply and Logistics Market: impact analysis
3. North America Neurology Clinical Trials Marketrevenue, By Phase  ,2018–2028(USD Billion)
4. North America Neurology Clinical Trials Marketrevenue, By Study Design ,2018–2028(USD Billion)
5. The U.S. Neurology Clinical Trials Marketrevenue, By Phase  ,2018–2028(USD Billion)
6. The U.S. Neurology Clinical Trials Marketrevenue, By Study Design ,2018–2028(USD Billion)
7. Rest of North America Neurology Clinical Trials Marketrevenue, By Phase  ,2018–2028(USD Billion)
8. Rest of North America Neurology Clinical Trials Marketrevenue, By Study Design ,2018–2028(USD Billion)
9. Europe Neurology Clinical Trials Marketrevenue, By Phase  ,2018–2028(USD Billion)
10. Europe Neurology Clinical Trials Marketrevenue, By Study Design ,2018–2028(USD Billion)
11. UK Neurology Clinical Trials Marketrevenue, By Phase  ,2018–2028(USD Billion)
12. UK Neurology Clinical Trials Marketrevenue, By Study Design ,2018–2028(USD Billion)
13. France Neurology Clinical Trials Marketrevenue, By Phase  ,2018–2028(USD Billion)
14. France Neurology Clinical Trials Marketrevenue, By Study Design ,2018–2028(USD Billion)
15. Germany Neurology Clinical Trials Marketrevenue, By Phase  ,2018–2028(USD Billion)
16. Germany Neurology Clinical Trials Marketrevenue, By Study Design ,2018–2028(USD Billion)
17. Rest of Europe Neurology Clinical Trials Marketrevenue, By Phase  ,2018–2028(USD Billion)
18. Rest of Europe Neurology Clinical Trials Marketrevenue, By Study Design ,2018–2028(USD Billion)
19. Asia Pacific Neurology Clinical Trials Marketrevenue, By Phase  ,2018–2028(USD Billion)
20. Asia Pacific Neurology Clinical Trials Marketrevenue, By Study Design ,2018–2028(USD Billion)
21. China Neurology Clinical Trials Marketrevenue, By Phase  ,2018–2028(USD Billion)
22. China Neurology Clinical Trials Marketrevenue, By Study Design ,2018–2028(USD Billion)
23. Japan Neurology Clinical Trials Marketrevenue, By Phase  ,2018–2028(USD Billion)
24. Japan Neurology Clinical Trials Marketrevenue, By Study Design ,2018–2028(USD Billion)
25. India Neurology Clinical Trials Marketrevenue, By Phase  ,2018–2028(USD Billion)
26. India Neurology Clinical Trials Marketrevenue, By Study Design ,2018–2028(USD Billion)
27. Rest of Asia Pacific Neurology Clinical Trials Marketrevenue, By Phase  ,2018–2028(USD Billion)
28. Rest of North America Neurology Clinical Trials Marketrevenue, By Study Design ,2018–2028(USD Billion)
29. Latin America Neurology Clinical Trials Marketrevenue, By Phase  ,2018–2028(USD Billion)
30. Latin America Neurology Clinical Trials Marketrevenue, By Study Design ,2018–2028(USD Billion)
31. Brazil Neurology Clinical Trials Marketrevenue, By Phase  ,2018–2028(USD Billion)
32. Brazil Neurology Clinical Trials Marketrevenue, By Study Design ,2018–2028(USD Billion)
33. Rest of Latin America Neurology Clinical Trials Marketrevenue, By Phase  ,2018–2028(USD Billion)
34. Rest of Latin America Neurology Clinical Trials Marketrevenue, By Study Design ,2018–2028(USD Billion)
35. The Middle East and Africa Neurology Clinical Trials Marketrevenue, By Phase  ,2018–2028(USD Billion)
36. The Middle East and Africa Neurology Clinical Trials Marketrevenue, By Study Design ,2018–2028(USD Billion)
37. Saudi Arabia Neurology Clinical Trials Marketrevenue, By Phase  ,2018–2028(USD Billion)
38. Saudi Arabia Neurology Clinical Trials Marketrevenue, By Study Design ,2018–2028(USD Billion)
39. South Africa Neurology Clinical Trials Marketrevenue, By Phase  ,2018–2028(USD Billion)
40. South Africa Neurology Clinical Trials Marketrevenue, By Study Design ,2018–2028(USD Billion)
41. Rest of the Middle East & Africa Neurology Clinical Trials Marketrevenue, By Phase  ,2018–2028(USD Billion)
42. Rest of the Middle East & Africa Neurology Clinical Trials Marketrevenue, By Study Design ,2018–2028(USD Billion)